M&A / Deals NewLimit’s $435M megaround; Lilly’s busy dealmaking week BioPharma DiveThe anti-aging biotech has secured one of the year s biggest venture fundings to bring its first drug into testing.Read full story pharminent June 3, 2026 (Last updated: June 4, 2026) BioPharma Dive The anti-aging biotech has secured one of the year s biggest venture fundings to bring its first drug into testing. Read full story Post navigation Previous: Travere beefs up rare kidney disease portfolio with up to $1.1B China dealNext: Legend surges on early data for ‘in vivo’ lymphoma cell therapy Related Stories M&A / Deals Solstice Oncology secures $225m to drive porustobart’s development for cancer pharminent September 10, 2026 M&A / Deals UK’s Claret Capital raises 575m for European biotechs pharminent September 7, 2026 M&A / Deals GSK wagers up to $1.3B on a different kind of cancer drug pharminent September 3, 2026